Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Data indicate 1 in 3 US adults unaware of connection between HPV and cancers

2.

Breast density changes over time are associated with an increased risk of cancer.

3.

Best foot forward—chemo care should include podiatry, say researchers

4.

FDA Greenlights First Engineered Cell Therapy for a Solid Tumor

5.

What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot